Share Price and Basic Stock Data
Last Updated: October 28, 2025, 6:49 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Panacea Biotec Ltd operates in the pharmaceuticals sector, with a market capitalization of ₹2,713 Cr and a share price of ₹443. The company’s revenue trends show a fluctuating performance over the past quarters. For instance, sales rose from ₹110.70 Cr in June 2022 to ₹150.50 Cr by December 2023, peaking at ₹166.70 Cr in June 2025. However, the company recorded a decline to ₹136.46 Cr in March 2024, indicating volatility in revenue generation. The trailing twelve months (TTM) revenue stood at ₹610 Cr, slightly improved from the ₹559 Cr reported for both FY 2024 and FY 2025. Such trends suggest that Panacea Biotec is struggling to maintain consistent sales growth, which is critical in the competitive pharmaceuticals industry, where sector players typically report stable or increasing sales figures. Overall, the revenue performance reflects both the challenges and opportunities within this dynamic sector.
Profitability and Efficiency Metrics
In terms of profitability, Panacea Biotec reported a negative operating profit margin (OPM) of -0.71%, underscoring operational inefficiencies. The company has consistently faced negative operating profits, with the most significant operating loss recorded at ₹-79.81 Cr in June 2022, gradually improving but remaining negative in subsequent quarters. The net profit also reflected challenges, standing at ₹11 Cr as of the latest reporting period, with quarterly net profits fluctuating between losses and small gains over the last year. The interest coverage ratio (ICR) was reported at -1.35x, indicating that the company struggles to generate sufficient earnings to cover interest expenses, a concerning sign for potential investors. Additionally, the return on equity (ROE) and return on capital employed (ROCE) were recorded at 4.92% and 4.57%, respectively, both below typical industry benchmarks, highlighting inefficiencies in capital utilization.
Balance Sheet Strength and Financial Ratios
Panacea Biotec’s balance sheet reveals a mix of strengths and weaknesses. The company has total borrowings of ₹22 Cr against reserves of ₹829 Cr, suggesting a manageable debt level relative to its equity. The current ratio stood at 1.49, indicating sufficient liquidity to cover short-term obligations, while the quick ratio of 0.90 suggests potential liquidity challenges in meeting immediate liabilities without relying on inventory. The price-to-book value (P/BV) ratio was reported at 3.24x, which is relatively high compared to typical sector ranges, possibly indicating overvaluation. The asset turnover ratio of 0.44% reflects below-average efficiency in asset utilization, which could hinder profitability. Overall, while the balance sheet shows reasonable liquidity and low debt levels, the company’s profitability ratios and asset efficiency metrics raise concerns about its financial health and operational performance.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Panacea Biotec indicates a strong promoter presence, with promoters holding 72.48% of the shares. Foreign institutional investors (FIIs) accounted for 0.79%, while domestic institutional investors (DIIs) held 1.52%, suggesting limited institutional interest. Public shareholding was recorded at 25.20%, with the number of shareholders standing at 34,256. The relatively stable promoter holding reflects confidence in the company’s long-term prospects, even as FII interest remains low, which could signal caution among foreign investors. The gradual decline in public shareholding from 25.98% in September 2022 to 25.20% in March 2025 also suggests that some retail investors may be exiting, possibly due to the company’s ongoing operational challenges and profitability concerns. Overall, while promoter confidence is a positive indicator, the low institutional participation raises potential red flags regarding broader market sentiment towards the company.
Outlook, Risks, and Final Insight
Looking ahead, Panacea Biotec faces several risks and opportunities. The company’s ongoing operational inefficiencies, highlighted by negative profit margins and low interest coverage ratios, pose significant challenges to its financial stability. Moreover, the fluctuating sales figures indicate a lack of consistency in revenue generation, which could hinder future growth. However, the manageable debt levels and strong promoter backing could provide a foundation for recovery if operational improvements are made. Additionally, the pharmaceutical sector’s potential for growth, especially in emerging markets, offers avenues for revenue enhancement. If the company can stabilize its operations and improve profitability, it may attract greater investor confidence and institutional interest. Conversely, failure to address these operational issues could lead to further declines in shareholder value and market perception, impacting its long-term viability in a competitive industry.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Panacea Biotec Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 144 Cr. | 114 | 247/84.3 | 32.8 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.80 Cr. | 1.99 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 5,012 Cr. | 460 | 480/192 | 112 | 22.8 | 0.14 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.6 Cr. | 48.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 32.8 Cr. | 22.4 | 29.1/17.0 | 34.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,773.41 Cr | 1,180.23 | 50.42 | 194.36 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 110.70 | 105.12 | 115.20 | 128.93 | 129.19 | 143.02 | 150.50 | 136.46 | 115.72 | 147.35 | 163.49 | 132.53 | 166.70 |
| Expenses | 190.51 | 108.96 | 123.84 | 134.60 | 139.50 | 146.58 | 150.65 | 142.50 | 129.71 | 140.35 | 155.53 | 159.41 | 167.88 |
| Operating Profit | -79.81 | -3.84 | -8.64 | -5.67 | -10.31 | -3.56 | -0.15 | -6.04 | -13.99 | 7.00 | 7.96 | -26.88 | -1.18 |
| OPM % | -72.10% | -3.65% | -7.50% | -4.40% | -7.98% | -2.49% | -0.10% | -4.43% | -12.09% | 4.75% | 4.87% | -20.28% | -0.71% |
| Other Income | 39.95 | 38.22 | 41.71 | 34.44 | 33.82 | 6.00 | 8.46 | 13.55 | 6.54 | 7.42 | 6.39 | 36.30 | 16.99 |
| Interest | 1.25 | 1.18 | 0.96 | 1.05 | 1.00 | 0.91 | 0.85 | 0.82 | 0.87 | 0.98 | 0.99 | 1.04 | 0.86 |
| Depreciation | 10.05 | 9.89 | 9.67 | 9.51 | 9.48 | 9.31 | 9.11 | 8.81 | 8.73 | 8.68 | 8.98 | 8.42 | 8.39 |
| Profit before tax | -51.16 | 23.31 | 22.44 | 18.21 | 13.03 | -7.78 | -1.65 | -2.12 | -17.05 | 4.76 | 4.38 | -0.04 | 6.56 |
| Tax % | 9.73% | 32.65% | 13.68% | 169.63% | 15.73% | 6.56% | 33.33% | -6.13% | -6.86% | 1.05% | -1.37% | 4,875.00% | 39.63% |
| Net Profit | -56.14 | 15.70 | 19.37 | -12.68 | 10.98 | -8.29 | -2.20 | -1.99 | -15.88 | 4.71 | 4.44 | -1.99 | 3.96 |
| EPS in Rs | -9.16 | 2.56 | 3.16 | -2.07 | 1.79 | -1.35 | -0.37 | -0.32 | -2.58 | 0.78 | 0.74 | -0.31 | 0.66 |
Last Updated: August 20, 2025, 5:45 am
Below is a detailed analysis of the quarterly data for Panacea Biotec Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 166.70 Cr.. The value appears strong and on an upward trend. It has increased from 132.53 Cr. (Mar 2025) to 166.70 Cr., marking an increase of 34.17 Cr..
- For Expenses, as of Jun 2025, the value is 167.88 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 159.41 Cr. (Mar 2025) to 167.88 Cr., marking an increase of 8.47 Cr..
- For Operating Profit, as of Jun 2025, the value is -1.18 Cr.. The value appears strong and on an upward trend. It has increased from -26.88 Cr. (Mar 2025) to -1.18 Cr., marking an increase of 25.70 Cr..
- For OPM %, as of Jun 2025, the value is -0.71%. The value appears strong and on an upward trend. It has increased from -20.28% (Mar 2025) to -0.71%, marking an increase of 19.57%.
- For Other Income, as of Jun 2025, the value is 16.99 Cr.. The value appears to be declining and may need further review. It has decreased from 36.30 Cr. (Mar 2025) to 16.99 Cr., marking a decrease of 19.31 Cr..
- For Interest, as of Jun 2025, the value is 0.86 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.04 Cr. (Mar 2025) to 0.86 Cr., marking a decrease of 0.18 Cr..
- For Depreciation, as of Jun 2025, the value is 8.39 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 8.42 Cr. (Mar 2025) to 8.39 Cr., marking a decrease of 0.03 Cr..
- For Profit before tax, as of Jun 2025, the value is 6.56 Cr.. The value appears strong and on an upward trend. It has increased from -0.04 Cr. (Mar 2025) to 6.56 Cr., marking an increase of 6.60 Cr..
- For Tax %, as of Jun 2025, the value is 39.63%. The value appears to be improving (decreasing) as expected. It has decreased from 4,875.00% (Mar 2025) to 39.63%, marking a decrease of 4,835.37%.
- For Net Profit, as of Jun 2025, the value is 3.96 Cr.. The value appears strong and on an upward trend. It has increased from -1.99 Cr. (Mar 2025) to 3.96 Cr., marking an increase of 5.95 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.66. The value appears strong and on an upward trend. It has increased from -0.31 (Mar 2025) to 0.66, marking an increase of 0.97.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:42 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 510 | 687 | 653 | 544 | 593 | 457 | 544 | 625 | 661 | 460 | 559 | 559 | 610 |
| Expenses | 582 | 643 | 541 | 505 | 509 | 591 | 490 | 548 | 674 | 558 | 574 | 584 | 623 |
| Operating Profit | -72 | 44 | 112 | 39 | 84 | -134 | 54 | 77 | -13 | -98 | -15 | -25 | -13 |
| OPM % | -14% | 6% | 17% | 7% | 14% | -29% | 10% | 12% | -2% | -21% | -3% | -4% | -2% |
| Other Income | 183 | 28 | 70 | 62 | 8 | 338 | -14 | 9 | 1,687 | 154 | 57 | 55 | 67 |
| Interest | 150 | 105 | 127 | 101 | 101 | 105 | 174 | 185 | 181 | 4 | 4 | 4 | 4 |
| Depreciation | 71 | 67 | 73 | 68 | 57 | 54 | 43 | 46 | 44 | 39 | 37 | 35 | 34 |
| Profit before tax | -111 | -99 | -19 | -67 | -66 | 45 | -178 | -146 | 1,449 | 13 | 1 | -8 | 16 |
| Tax % | 2% | 3% | 10% | -16% | 15% | 17% | 9% | 1% | 26% | 363% | 201% | 10% | |
| Net Profit | -113 | -108 | -21 | -56 | -76 | 38 | -194 | -148 | 1,078 | -34 | -2 | -9 | 11 |
| EPS in Rs | -18.29 | -17.38 | -2.98 | -8.89 | -12.07 | 6.15 | -31.69 | -24.09 | 175.91 | -5.42 | -0.19 | -1.37 | 1.87 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 4.42% | 80.56% | -166.67% | -35.71% | 150.00% | -610.53% | 23.71% | 828.38% | -103.15% | 94.12% | -350.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 76.13% | -247.22% | 130.95% | 185.71% | -760.53% | 634.24% | 804.67% | -931.53% | 197.27% | -444.12% |
Panacea Biotec Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 1% |
| 3 Years: | -5% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 12% |
| 3 Years: | 21% |
| TTM: | 29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 19% |
| 3 Years: | 43% |
| 1 Year: | 71% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -6% |
| Last Year: | -5% |
Last Updated: September 5, 2025, 12:05 pm
Balance Sheet
Last Updated: October 10, 2025, 2:41 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 507 | 449 | 426 | 350 | 303 | 344 | 193 | -235 | 871 | 837 | 836 | 829 |
| Borrowings | 1,060 | 1,111 | 1,105 | 994 | 941 | 646 | 742 | 820 | 34 | 20 | 21 | 22 |
| Other Liabilities | 371 | 364 | 317 | 440 | 349 | 379 | 449 | 587 | 848 | 407 | 378 | 433 |
| Total Liabilities | 1,943 | 1,930 | 1,854 | 1,789 | 1,598 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 |
| Fixed Assets | 1,276 | 1,144 | 1,071 | 1,001 | 949 | 806 | 657 | 609 | 622 | 600 | 582 | 567 |
| CWIP | 172 | 155 | 161 | 30 | 40 | 23 | 24 | 34 | 17 | 42 | 102 | 128 |
| Investments | 16 | 15 | 9 | 7 | 7 | 5 | 6 | 0 | 5 | 13 | 40 | 3 |
| Other Assets | 479 | 616 | 614 | 750 | 602 | 542 | 703 | 534 | 1,114 | 615 | 517 | 592 |
| Total Assets | 1,943 | 1,930 | 1,854 | 1,789 | 1,598 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 |
Below is a detailed analysis of the balance sheet data for Panacea Biotec Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 6.00 Cr..
- For Reserves, as of Mar 2025, the value is 829.00 Cr.. The value appears to be declining and may need further review. It has decreased from 836.00 Cr. (Mar 2024) to 829.00 Cr., marking a decrease of 7.00 Cr..
- For Borrowings, as of Mar 2025, the value is 22.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 21.00 Cr. (Mar 2024) to 22.00 Cr., marking an increase of 1.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 433.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 378.00 Cr. (Mar 2024) to 433.00 Cr., marking an increase of 55.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,290.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,241.00 Cr. (Mar 2024) to 1,290.00 Cr., marking an increase of 49.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 567.00 Cr.. The value appears to be declining and may need further review. It has decreased from 582.00 Cr. (Mar 2024) to 567.00 Cr., marking a decrease of 15.00 Cr..
- For CWIP, as of Mar 2025, the value is 128.00 Cr.. The value appears strong and on an upward trend. It has increased from 102.00 Cr. (Mar 2024) to 128.00 Cr., marking an increase of 26.00 Cr..
- For Investments, as of Mar 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 40.00 Cr. (Mar 2024) to 3.00 Cr., marking a decrease of 37.00 Cr..
- For Other Assets, as of Mar 2025, the value is 592.00 Cr.. The value appears strong and on an upward trend. It has increased from 517.00 Cr. (Mar 2024) to 592.00 Cr., marking an increase of 75.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,290.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,241.00 Cr. (Mar 2024) to 1,290.00 Cr., marking an increase of 49.00 Cr..
Notably, the Reserves (829.00 Cr.) exceed the Borrowings (22.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -73.00 | 43.00 | 111.00 | -955.00 | -857.00 | -780.00 | -688.00 | -743.00 | -47.00 | -118.00 | -36.00 | -47.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 52 | 79 | 95 | 84 | 71 | 46 | 49 | 45 | 48 | 37 | 47 |
| Inventory Days | 375 | 404 | 516 | 770 | 651 | 173 | 344 | 311 | 296 | 292 | 282 | 391 |
| Days Payable | 430 | 272 | 318 | 607 | 540 | 572 | 463 | 440 | 327 | 256 | 244 | 413 |
| Cash Conversion Cycle | 13 | 184 | 278 | 259 | 195 | -328 | -73 | -80 | 14 | 83 | 76 | 25 |
| Working Capital Days | -343 | -126 | 27 | -46 | -96 | -363 | 95 | -43 | -229 | -5 | -2 | 46 |
| ROCE % | -8% | 0% | 4% | 2% | 3% | -16% | 4% | 5% | -6% | -10% | -4% | -5% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 117 | 0.02 | 0 | 117 | 2025-04-22 17:25:23 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | -1.37 | -0.19 | -5.43 | 175.98 | -24.11 |
| Diluted EPS (Rs.) | -1.37 | -0.19 | -5.43 | 175.98 | -24.11 |
| Cash EPS (Rs.) | 4.26 | 5.75 | 0.87 | 183.11 | -16.68 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 136.18 | 133.94 | 133.63 | 138.09 | -41.36 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 136.18 | 133.94 | 133.63 | 138.09 | -41.36 |
| Revenue From Operations / Share (Rs.) | 91.21 | 91.29 | 75.09 | 107.96 | 102.01 |
| PBDIT / Share (Rs.) | -0.85 | 0.93 | -7.56 | -0.47 | 14.14 |
| PBIT / Share (Rs.) | -6.54 | -5.06 | -13.95 | -7.60 | 6.70 |
| PBT / Share (Rs.) | -1.30 | 0.24 | 2.09 | 236.54 | -23.56 |
| Net Profit / Share (Rs.) | -1.42 | -0.24 | -5.51 | 175.98 | -24.12 |
| NP After MI And SOA / Share (Rs.) | -1.37 | -0.19 | -5.43 | 175.98 | -24.11 |
| PBDIT Margin (%) | -0.93 | 1.02 | -10.06 | -0.43 | 13.86 |
| PBIT Margin (%) | -7.16 | -5.53 | -18.57 | -7.04 | 6.56 |
| PBT Margin (%) | -1.42 | 0.26 | 2.78 | 219.10 | -23.09 |
| Net Profit Margin (%) | -1.55 | -0.26 | -7.33 | 163.01 | -23.64 |
| NP After MI And SOA Margin (%) | -1.49 | -0.20 | -7.22 | 163.01 | -23.63 |
| Return on Networth / Equity (%) | -1.00 | -0.14 | -4.04 | 126.99 | 0.00 |
| Return on Capital Employeed (%) | -4.34 | -3.32 | -9.09 | -4.75 | 5.44 |
| Return On Assets (%) | -0.64 | -0.09 | -2.61 | 60.47 | -12.52 |
| Long Term Debt / Equity (X) | 0.02 | 0.01 | 0.01 | 0.03 | -2.92 |
| Total Debt / Equity (X) | 0.02 | 0.01 | 0.01 | 0.03 | -2.92 |
| Asset Turnover Ratio (%) | 0.44 | 0.44 | 0.30 | 0.24 | 0.31 |
| Current Ratio (X) | 1.49 | 1.57 | 1.71 | 1.30 | 1.20 |
| Quick Ratio (X) | 0.90 | 0.99 | 1.10 | 1.03 | 0.79 |
| Inventory Turnover Ratio (X) | 1.09 | 1.11 | 1.02 | 1.14 | 0.58 |
| Interest Coverage Ratio (X) | -1.35 | 1.60 | -10.43 | -0.01 | 0.46 |
| Interest Coverage Ratio (Post Tax) (X) | -10.52 | -9.48 | -29.74 | -2.31 | 0.21 |
| Enterprise Value (Cr.) | 2612.25 | 620.65 | 454.38 | 355.93 | 1682.86 |
| EV / Net Operating Revenue (X) | 4.67 | 1.11 | 0.98 | 0.53 | 2.69 |
| EV / EBITDA (X) | -497.57 | 108.22 | -9.81 | -122.86 | 19.43 |
| MarketCap / Net Operating Revenue (X) | 4.83 | 1.33 | 1.44 | 1.37 | 1.74 |
| Price / BV (X) | 3.24 | 0.90 | 0.80 | 1.07 | -4.34 |
| Price / Net Operating Revenue (X) | 4.83 | 1.33 | 1.44 | 1.37 | 1.74 |
| EarningsYield | 0.00 | 0.00 | -0.05 | 1.19 | -0.13 |
After reviewing the key financial ratios for Panacea Biotec Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -1.37. This value is below the healthy minimum of 5. It has decreased from -0.19 (Mar 24) to -1.37, marking a decrease of 1.18.
- For Diluted EPS (Rs.), as of Mar 25, the value is -1.37. This value is below the healthy minimum of 5. It has decreased from -0.19 (Mar 24) to -1.37, marking a decrease of 1.18.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.26. This value is within the healthy range. It has decreased from 5.75 (Mar 24) to 4.26, marking a decrease of 1.49.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 136.18. It has increased from 133.94 (Mar 24) to 136.18, marking an increase of 2.24.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 136.18. It has increased from 133.94 (Mar 24) to 136.18, marking an increase of 2.24.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 91.21. It has decreased from 91.29 (Mar 24) to 91.21, marking a decrease of 0.08.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.85. This value is below the healthy minimum of 2. It has decreased from 0.93 (Mar 24) to -0.85, marking a decrease of 1.78.
- For PBIT / Share (Rs.), as of Mar 25, the value is -6.54. This value is below the healthy minimum of 0. It has decreased from -5.06 (Mar 24) to -6.54, marking a decrease of 1.48.
- For PBT / Share (Rs.), as of Mar 25, the value is -1.30. This value is below the healthy minimum of 0. It has decreased from 0.24 (Mar 24) to -1.30, marking a decrease of 1.54.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -1.42. This value is below the healthy minimum of 2. It has decreased from -0.24 (Mar 24) to -1.42, marking a decrease of 1.18.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -1.37. This value is below the healthy minimum of 2. It has decreased from -0.19 (Mar 24) to -1.37, marking a decrease of 1.18.
- For PBDIT Margin (%), as of Mar 25, the value is -0.93. This value is below the healthy minimum of 10. It has decreased from 1.02 (Mar 24) to -0.93, marking a decrease of 1.95.
- For PBIT Margin (%), as of Mar 25, the value is -7.16. This value is below the healthy minimum of 10. It has decreased from -5.53 (Mar 24) to -7.16, marking a decrease of 1.63.
- For PBT Margin (%), as of Mar 25, the value is -1.42. This value is below the healthy minimum of 10. It has decreased from 0.26 (Mar 24) to -1.42, marking a decrease of 1.68.
- For Net Profit Margin (%), as of Mar 25, the value is -1.55. This value is below the healthy minimum of 5. It has decreased from -0.26 (Mar 24) to -1.55, marking a decrease of 1.29.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -1.49. This value is below the healthy minimum of 8. It has decreased from -0.20 (Mar 24) to -1.49, marking a decrease of 1.29.
- For Return on Networth / Equity (%), as of Mar 25, the value is -1.00. This value is below the healthy minimum of 15. It has decreased from -0.14 (Mar 24) to -1.00, marking a decrease of 0.86.
- For Return on Capital Employeed (%), as of Mar 25, the value is -4.34. This value is below the healthy minimum of 10. It has decreased from -3.32 (Mar 24) to -4.34, marking a decrease of 1.02.
- For Return On Assets (%), as of Mar 25, the value is -0.64. This value is below the healthy minimum of 5. It has decreased from -0.09 (Mar 24) to -0.64, marking a decrease of 0.55.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.44. There is no change compared to the previous period (Mar 24) which recorded 0.44.
- For Current Ratio (X), as of Mar 25, the value is 1.49. This value is below the healthy minimum of 1.5. It has decreased from 1.57 (Mar 24) to 1.49, marking a decrease of 0.08.
- For Quick Ratio (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.90, marking a decrease of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 4. It has decreased from 1.11 (Mar 24) to 1.09, marking a decrease of 0.02.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1.35. This value is below the healthy minimum of 3. It has decreased from 1.60 (Mar 24) to -1.35, marking a decrease of 2.95.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -10.52. This value is below the healthy minimum of 3. It has decreased from -9.48 (Mar 24) to -10.52, marking a decrease of 1.04.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,612.25. It has increased from 620.65 (Mar 24) to 2,612.25, marking an increase of 1,991.60.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.67. This value exceeds the healthy maximum of 3. It has increased from 1.11 (Mar 24) to 4.67, marking an increase of 3.56.
- For EV / EBITDA (X), as of Mar 25, the value is -497.57. This value is below the healthy minimum of 5. It has decreased from 108.22 (Mar 24) to -497.57, marking a decrease of 605.79.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.83. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 4.83, marking an increase of 3.50.
- For Price / BV (X), as of Mar 25, the value is 3.24. This value exceeds the healthy maximum of 3. It has increased from 0.90 (Mar 24) to 3.24, marking an increase of 2.34.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.83. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 4.83, marking an increase of 3.50.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Panacea Biotec Ltd:
- Net Profit Margin: -1.55%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -4.34% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -1% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -10.52
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.9
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 50.42)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -1.55%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Ambala-Chandigarh Highway, Lalru Punjab 140501 | companysec@panaceabiotec.com http://www.panaceabiotec.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Rajesh Jain | Chairman & Managing Director |
| Mr. Sandeep Jain | Joint Managing Director |
| Mr. Ankesh Jain | Whole Time Director |
| Mrs. Ambika Sharma | Non Executive Director |
| Mr. N N Khamitkar | Non Executive Director |
| Mr. Mukul Gupta | Non Executive Director |
| Mr. Narotam Kumar Juneja | Non Executive Director |
| Mr. K M Lal | Non Executive Director |
| Mrs. Manjula Upadhyay | Non Executive Director |
| Mr. Bhupinder Singh | Non Executive Director |
FAQ
What is the intrinsic value of Panacea Biotec Ltd?
Panacea Biotec Ltd's intrinsic value (as of 28 October 2025) is 81.90 which is 81.47% lower the current market price of 442.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,711 Cr. market cap, FY2025-2026 high/low of 582/281, reserves of ₹829 Cr, and liabilities of 1,290 Cr.
What is the Market Cap of Panacea Biotec Ltd?
The Market Cap of Panacea Biotec Ltd is 2,711 Cr..
What is the current Stock Price of Panacea Biotec Ltd as on 28 October 2025?
The current stock price of Panacea Biotec Ltd as on 28 October 2025 is 442.
What is the High / Low of Panacea Biotec Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Panacea Biotec Ltd stocks is 582/281.
What is the Stock P/E of Panacea Biotec Ltd?
The Stock P/E of Panacea Biotec Ltd is .
What is the Book Value of Panacea Biotec Ltd?
The Book Value of Panacea Biotec Ltd is 136.
What is the Dividend Yield of Panacea Biotec Ltd?
The Dividend Yield of Panacea Biotec Ltd is 0.00 %.
What is the ROCE of Panacea Biotec Ltd?
The ROCE of Panacea Biotec Ltd is 4.57 %.
What is the ROE of Panacea Biotec Ltd?
The ROE of Panacea Biotec Ltd is 4.92 %.
What is the Face Value of Panacea Biotec Ltd?
The Face Value of Panacea Biotec Ltd is 1.00.